Dr. Peter Hotez also writes for the Washington Post along with Dr. Vin Gupta

Rumble with Michael Moore, Episode 225 (click here)

In this episode with Michael Moore, Dr. Peter Hotez speaks about his effort to vaccinate the world. The vaccine he developed can be produced in a sterile setting and he is willing to provide others sincerely interested in vaccinating people no matter the country with the start doses needed.

This is the article that discusses his accomplishments. If it makes a difference in the comfort with the vaccine, Houston is one of the blueberries in the Texas Red State.

October 19, 2021
By Karen Brooks Harper

Maria Bottazzi, left, and Peter Hotez at the Tropical Medicine Lab at Texas Children's Hospital Center for Vaccine Development in Houston on Oct. 5, 2021.

The day before COVID-19 (click here) claimed its first Texas victim in 2020, Dr. Peter Hotez was a guest on the popular Austin-based podcast “The Drive.”

After 10 years of research into coronavirus vaccines, Hotez and his Houston team needed an infusion of cash to build on their past work and make a vaccine that could, as Hotez told listeners then, “rescue the world” from the deadly emerging coronavirus pandemic.

“You’d think that people would be pretty eager to support us to move this forward, but so far it hasn’t happened,” the Houston pediatrician and vaccine scientist told the host, Dr. Peter Attia, on March 14, 2020....

...Now, nearly 18 months later, the Houston team’s vaccine, called Corbevax by its maker in India, is cheap, has no patent, can be made by many vaccine producers globally — including those in low- and middle-income countries — and is poised to receive approval for widespread global use.

The Indian government has promised the biopharmaceutical company Biological E Limited, which is making the vaccine in that country, that it will buy 300 million doses with the potential for more.

A halal version of the vaccine, for use in Islamic countries because it doesn’t contain animal-based ingredients, is also about to start clinical trials in Indonesia.

And later this year, the company hopes the vaccine will be endorsed by the World Health Organization for use globally, which could open the doors to quicker authorization in several countries that need it....

Dr. Hotez does all the work no one else seems to take on with  chagas and schistosomiasis. He has now developed a RBD based vaccine for SARS-CoV-2. This is not an mRNA vaccine.

This is an article about RBD based vaccines in relation to this virus. When Dr. Hotez heard the call for "all hands on deck" he didn't hesitate to perfect the ability for this vaccine to be ready to assist in a global innoculation.

Maria Bottazzi holds a vial of the RBD-based SARS-CoV-2 vaccine at the Tropical Medicine Lab at Texas Children's Hospital Center for Vaccine Development in Houston on Oct. 5, 2021.

Scientific rationale for developing potent RBD-based vaccines targeting COVID-19

• By Harry Kleanthous, 
• Judith Maxwell Silverman, 
• Karen W. Makar, 
• In-Kyu Yoon, 
• Nicholas Jackson & 
• David W. Vaughn 

Published in npj Vaccines volume 6, Article number: 128 (2021)

Vaccination of the global population against COVID-19 (click here) is a great scientific, logistical, and moral challenge. Despite the rapid development and authorization of several full-length Spike (S) protein vaccines, the global demand outweighs the current supply and there is a need for safe, potent, high-volume, affordable vaccines that can fill this gap, especially in low- and middle-income countries. Whether SARS-CoV-2 S-protein receptor-binding domain (RBD)-based vaccines could fill this gap has been debated, especially with regards to its suitability to protect against emerging viral variants of concern. Given a predominance for elicitation of neutralizing antibodies (nAbs) that target RBD following natural infection or vaccination, a key biomarker of protection, there is merit for selection of RBD as a sole vaccine immunogen. With its high-yielding production and manufacturing potential, RBD-based vaccines offer an abundance of temperature-stable doses at an affordable cost....